Lung Cancer Diagnostics

Global Market Trajectory & Analytics

MCP16923

EXECUTIVE ENGAGEMENTS

POOL

3123
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

562
Interactions with Platform & by Email

PARTICIPANTS

94
Unique # Participated

VALIDATIONS

27
Responses Validated*

COMPANIES

48
Responses Validated*
* Login for a full stack data experience

DATE

MAY 2021

TABLES

306

PAGES

605

EDITION

8

PRICE

USD 5450

CODE

MCP16923


COMPETITIVE METRICS

COMPANY

D S N T

% *

Abbott Diagnostics

Admera Health

Agena Bioscience, Inc.

Agilent Technologies, Inc.

Asuragen, Inc.

BGI Genomics Co Ltd.

Biocartis NV

Biocept, Inc.

Biodesix, Inc.

Bioprognos SL

*Login to Participate & View Data Stacks
View 48 Companies...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Global Lung Cancer Diagnostics Market to Reach $3 Billion by 2024

Lung cancer represents the leading cause of cancer deaths globally. The disease is categorized into Small-cell Lung Cancer (SCLC) and Non-small cell lung cancer (NSCLC), with the latter constituting for about 80-85% of cases. Early detection of lung cancer, for both NSCLC and SCLC, is taking increased precedence globally which in turn spurs demand for lung cancer diagnostics. Amid the COVID-19 crisis, the global market for Lung Cancer Diagnostics is projected to reach US$3 Billion by 2024, registering a compounded annual growth rate (CAGR) of 8.0% over the analysis period. United States represents the largest regional market for Lung Cancer Diagnostics, accounting for an estimated 27.0% share of the global total. The market is projected to reach US$803.9 Million by the close of the analysis period. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 11.3% over the analysis period.

The market is driven by rising incidence of lung cancer, increasing awareness levels about the symptoms and the seriousness of the condition, technological advancements, and new product launches. Increased focus on the development of lung cancer-specific biomarkers bodes well for the market growth. The ability of such diagnostic tools to enable personalized treatment for lung malignancies fuels market growth. The rapid rise in the number of smokers in developing regions also represents an important growth driver for the lung cancer diagnostics market. Significant advancements in diagnosis and early detection are transforming the lung cancer treatment landscape. High prevalence rate of Non-Small Cell Lung Cancer (NSCLC) is especially driving interest in the diagnostic value offered by liquid biopsies. The US holds the largest market share, owing to key factors such as growing patient awareness, high market penetration of innovative and technologically advanced products, and rapid urbanization and industrial development. The increasing prevalence of lung cancer in the region driven by increase in risk factors like cigarette smoking, exposure to second hand smoke, occupational exposure to cancer causing chemicals, has spurred the development of innovative and advanced diagnostic solutions. Growth in Asia-Pacific region is fueled by key growth drivers, such as rising awareness of symptoms of lung cancer, emerging demand for advanced lung cancer diagnostic tools, improving healthcare infrastructure, and large base of patients with unmet clinical needs. Rising healthcare expenditure and the presence of a large patient pool in countries like India and China is expected to unfurl significant growth opportunities.

The market for molecular tests is forecast to grow the fastest over the analysis period. Molecular tests are generally done on tissue from biopsy or surgery, as well as on blood taken from a vein. The rapid pace of advancements and innovations in the area of molecular diagnostic technology are leading to the development and launch of several new types of diagnostic test techniques, aiding use of molecular tests for lung cancer diagnosis. The use of molecular tests for lung cancer diagnosis also facilitates in developing personalized treatments. Sustained increase in investments into R&D initiatives for developing biomarker-based molecular testing for lung cancer detection will also support segment growth.

SELECT PLAYERS

Abbott Diagnostics - Core Laboratory; Dr Lal PathLabs; F. Hoffmann-La Roche AG; Illumina Inc.; Myriad Genetics Inc.; NanoString Technologies; NeoGenomics Laboratories Inc.; PlexBio Co., Ltd.; QIAGEN GmbH; Quest Diagnostics; Thermo Fisher Scientific Inc.

SEGMENTS

» Test (Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy, and Other Tests) » Type (Non-Small-Cell Lung Cancer (NSCLC), and Small-Cell Lung Cancer (SCLC) » and End-Use (Hospital Laboratories, Cancer Research Institutes, and Other End-Uses)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Early Detection of Lung Cancer Takes Precedence, Driving the Demand for Lung Cancer Diagnostics
Non-small Cell Lung Cancer - The More Prominent of the Two Lung Cancer Types
Imaging Tests Segment Dominates the Market, Molecular Tests Category to Witness High Growth
US Leads the Lung Cancer Diagnostics Market, Asia-Pacific to Witness Fastest Growth
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
Agilent Technologies Inc. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Illumina, Inc. (USA)
NeoGenomics Laboratories, Inc. (USA)
QIAGEN N.V. (The Netherlands)
Thermo Fisher Scientific, Inc. (USA)
Veracyte (USA)
3. MARKET TRENDS & DRIVERS
Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Early Diagnoses
Age-Standardized Lung Cancer Rates for Select Countries
Age-Standardized Lung Cancer Rates in Men for Select Countries
Age Standardized Lung Cancer Rates in Women for Select Countries
Lung Cancer-Specific Biomarkers to Spur Market Growth
Select Lung Cancer Biomarkers
New Potential Biomarker for Early Stage Lung Cancer Identified in a Recent NCI Study (2019)
Advancements and Research Initiatives in Lung Cancer Diagnostics Space
EFIRM Test for Detection of Lung Cancer-related EGFR Mutations in NSCLC Patients
A Glance at Select Recent Launches of Lung Cancer Diagnostic Tests
New Product Launches/Approvals in the Lung Cancer Diagnostics
Recent Approvals
Liquid Biopsies Grow in Value as a Diagnostic Tool Supporting Therapy Decisions in NSCLCs
Effervescent Rate of New Innovations & Product Development Will Make Liquid Biopsy a Readily Available Option for Patients in the Coming Years
High Cigarette Consumption/Rise in Prevalence of Smoking Increases the Incidence of Lung Cancer
Cigarette Consumption Per Year Per Person Across Select Countries: 2016
Top 15 Countries with the Highest Smoking Rates: 2015
Increasing Number of Awareness Programs for Lung Cancer and Symptoms
Growing Availability of Government/Private Funding for R&D to Develop Lung Cancer Diagnostics
Table: National Cancer Institute Research Funding for Lung Cancer in US$ Million for the Years 2014 through 2017
Aging Demographics & Unhealthy Lifestyles Raise the Risk of Cancer
Cancer Prone Sites based on Age
Table: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Lung Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Imaging Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Sputum Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Sputum Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Sputum Cytology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Molecular Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Molecular Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Molecular Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Small-Cell Lung Cancer (SCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Small-Cell Lung Cancer (SCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Small-Cell Lung Cancer (SCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospital Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cancer Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
UNITED STATES
Lung Cancer Stats
US Lung and Bronchus Cancer New Cases by Gender: 2019E
US Lung and Bronchus Cancer Deaths by Gender: 2019E
Incidence Rates* for Lung and Bronchus Cancer by Gender, 2011-2015
Death Rates* for Lung and Bronchus Cancer by Gender in the US, 2012-2016
Incidence Rates for Lung and Bronchus Cancer by Race/Ethnicity, 2011-2015
Reimbursement and Insurance Coverage for Lung Cancer Screening in the US
CY 2019 Medicare Physician Fee Payment Levels for Low Dose CT Scan (LDCT) Screening
CY 2019 Hospital Outpatient Prospective Payment System (HOPPS) Payment Levels for Low Dose CT Scan (LDCT) Screening
Oncimmune’s EarlyCDT Lung to be commercialized in the US by Biodesix (2019)
Market Analytics
USA Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
China Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
China Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Lung Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
France Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
France Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
UNITED KINGDOM
TABLE: UK Age-standardised Rate (per 100,00) of Lung Cancer Cases by Gender: 1980-2035P
UK Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
SPAIN
Spain Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Spain Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Spain Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
RUSSIA
Russia Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Russia Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Russia Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Lung Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
AUSTRALIA
Australia Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Australia Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Australia Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
INDIA
Rise in Incidence of Lung Cancer in India
Table: New Cancer Cases in India by Site: 2018
India Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
India Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
India Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
India Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
India Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
India Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
SOUTH KOREA
South Korea Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
South Korea Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
South Korea Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Rest of Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Rest of Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
LATIN AMERICA
Latin America Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Latin America Historic Review for Lung Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
ARGENTINA
Argentina Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Argentina Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Argentina Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
BRAZIL
Brazil Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Brazil Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Brazil Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
MEXICO
Mexico Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Mexico Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Mexico Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
REST OF LATIN AMERICA
Rest of Latin America Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Rest of Latin America Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Rest of Latin America Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
MIDDLE EAST
Middle East Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Middle East Historic Review for Lung Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
IRAN
Iran Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Iran Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Iran Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
ISRAEL
Israel Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Israel Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Israel Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
SAUDI ARABIA
Saudi Arabia Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Saudi Arabia Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Saudi Arabia Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
UNITED ARAB EMIRATES
UAE Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
UAE Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
UAE Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
REST OF MIDDLE EAST
Rest of Middle East Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Rest of Middle East Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Rest of Middle East Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
AFRICA
Africa Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Africa Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Africa Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
Total Companies Profiled: 48 (including Divisions/Subsidiaries - 48)

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com